Targeted mass spectrometry for monitoring of neural differentiation

Sucha R, Kubickova M, Cervenka J, Hruska-Plochan M, Bohaciakova D, Vodickova, Kepkova K, Novakova T, Budkova K, Susor A, Marsala M, Motlik J, Kovarova H, Vodicka P.

Biol Open. 2021 Aug 15;10(8):bio058727. doi: 10.1242/bio.058727. Epub 2021 Aug 6. PMID: 34357391; PMCID: PMC8353267.

Q2

23 Aug 2021

No description

Human multipotent neural stem cells could effectively be used for the treatment of a variety of neurological disorders. However, a defining signature of neural stem cell lines that would be expandable, non-tumorigenic, and differentiate into desirable neuronal/glial phenotype after in vivo grafting is not yet defined. Employing a mass spectrometry approach, based on selected reaction monitoring, we tested a panel of well-described culture conditions, and measured levels of protein markers routinely used to probe neural differentiation, i.e. POU5F1 (OCT4), SOX2, NES, DCX, TUBB3, MAP2, S100B, GFAP, GALC, and OLIG1. Our multiplexed assay enabled us to simultaneously identify the presence of pluripotent, multipotent, and lineage-committed neural cells, thus representing a powerful tool to optimize novel and highly specific propagation and differentiation protocols. The multiplexing capacity of this method permits the addition of other newly identified cell type-specific markers to further increase the specificity and quantitative accuracy in detecting targeted cell populations. Such an expandable assay may gain the advantage over traditional antibody-based assays, and represents a method of choice for quality control of neural stem cell lines intended for clinical use.

Keywords: Cell line characterization; Mass spectrometry; Neural differentiation; Neural stem cell; Protein marker; Selected reaction monitoring.


More articles

All articles

You are running an old browser version. We recommend updating your browser to its latest version.

More info